首页 > 最新文献

Digestive Surgery最新文献

英文 中文
Colonic Diverticulosis at Colonoscopy in Africa: A Systematic Review and Meta-Analysis of Pooled Estimates. 非洲结肠镜检查中的结肠憩室病:系统综述和汇总估算的荟萃分析。
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-02-20 DOI: 10.1159/000536587
Emeka Ray-Offor, Stella-Maris Egboh, Rex F O A Ijah, Sameh Hany Emile, Steven D Wexner

Introduction: There is need to ascertain any epidemiologic shift of diverticulosis among Africans with traditionally high fiber diet consumption patterns and rare diverticulosis prevalence.

Methods: We systematically searched PubMed, Scopus, Cochrane Library, African Journal Online (AJOL), and Google Scholar. Eligibility criteria included full-text observational and experimental human colonoscopy studies on asymptomatic and symptomatic African population from 1985 to 2022. Case reports, conference abstracts, dissertations, systematic reviews, and studies lacking colonoscopy findings were excluded. NIH quality assessment tool for observational cohort and cross-sectional studies was used to assess risk of bias. Meta-analysis was performed using the random-effect model. Heterogeneity was assessed using inconsistency (I2) statistics.

Results: Thirty studies were included. Pooled prevalence rate of colonic diverticulosis in the last decade (2012-2022) has increased to 9.7% (95% CI 6.5-13.4; I2 = 97.3%) from 3.5% (95% CI 1.4-6.4; I2 = 62.7%). The highest regional prevalence rate was in West African studies at 11.3% (95% CI 7.6-14.9; I2 = 96.2%). Proportion of individuals with diverticulosis ≥50 years and male sex were 86.9% (95% CI 80.5-92.1) and 65.2% (95% CI 55.0-74.8), respectively. The left colon had the highest diverticulosis frequency (37% [148/400]). Bleeding/inflammation complications were sparingly detected (OR 0.2 [95% CI 0.03-0.75; p < 0.0001]).

Conclusion: An increasing utilization of colonoscopy revealed approximately a threefold increase in the prevalence rate of colonic diverticulosis in Africa. This pathology was most common in males aged >50. Left colon was predominantly affected. Further studies are needed to demonstrate the effect of westernization of diet.

背景:有必要确定憩室病在传统高纤维饮食消费模式和罕见憩室病发病率的非洲人中的流行病学变化:我们系统地搜索了 PubMed、Scopus、Cochrane Library、African Journal Online (AJOL) 和 Google Scholar。资格标准包括 1985-2022 年间针对无症状和有症状非洲人群的观察性和实验性人类结肠镜检查全文研究。病例报告、会议摘要、学位论文、系统综述以及缺乏结肠镜检查结果的研究均被排除在外。采用 NIH 观察性队列和横断面研究质量评估工具来评估偏倚风险。采用随机效应模型进行 Meta 分析。使用不一致性(I2)统计量评估异质性:结果:共纳入 30 项研究。结肠憩室综合患病率为 9.1%(95%CI 7.1-11.2;I2=96.3%),西非研究的地区患病率最高,为 11.3%(95%CI 7.6-14.9;I2=96.2%)。年龄≥50岁的憩室患者比例和男性比例分别为86.9%(95%CI 80.5-92.1)和65.2%(95%CI 55.0-74.8)。左结肠憩室发生率最高[37%(148/400)]。很少发现出血/炎症并发症[OR 0.2 (95%CI 0.03-0.75;p结论:结肠憩室最常见于 50 岁以上的男性。受影响的主要是左侧结肠。据报道,非洲各地在发现结肠憩室方面存在地区差异。
{"title":"Colonic Diverticulosis at Colonoscopy in Africa: A Systematic Review and Meta-Analysis of Pooled Estimates.","authors":"Emeka Ray-Offor, Stella-Maris Egboh, Rex F O A Ijah, Sameh Hany Emile, Steven D Wexner","doi":"10.1159/000536587","DOIUrl":"10.1159/000536587","url":null,"abstract":"<p><strong>Introduction: </strong>There is need to ascertain any epidemiologic shift of diverticulosis among Africans with traditionally high fiber diet consumption patterns and rare diverticulosis prevalence.</p><p><strong>Methods: </strong>We systematically searched PubMed, Scopus, Cochrane Library, African Journal Online (AJOL), and Google Scholar. Eligibility criteria included full-text observational and experimental human colonoscopy studies on asymptomatic and symptomatic African population from 1985 to 2022. Case reports, conference abstracts, dissertations, systematic reviews, and studies lacking colonoscopy findings were excluded. NIH quality assessment tool for observational cohort and cross-sectional studies was used to assess risk of bias. Meta-analysis was performed using the random-effect model. Heterogeneity was assessed using inconsistency (I2) statistics.</p><p><strong>Results: </strong>Thirty studies were included. Pooled prevalence rate of colonic diverticulosis in the last decade (2012-2022) has increased to 9.7% (95% CI 6.5-13.4; I2 = 97.3%) from 3.5% (95% CI 1.4-6.4; I2 = 62.7%). The highest regional prevalence rate was in West African studies at 11.3% (95% CI 7.6-14.9; I2 = 96.2%). Proportion of individuals with diverticulosis ≥50 years and male sex were 86.9% (95% CI 80.5-92.1) and 65.2% (95% CI 55.0-74.8), respectively. The left colon had the highest diverticulosis frequency (37% [148/400]). Bleeding/inflammation complications were sparingly detected (OR 0.2 [95% CI 0.03-0.75; p &lt; 0.0001]).</p><p><strong>Conclusion: </strong>An increasing utilization of colonoscopy revealed approximately a threefold increase in the prevalence rate of colonic diverticulosis in Africa. This pathology was most common in males aged &gt;50. Left colon was predominantly affected. Further studies are needed to demonstrate the effect of westernization of diet.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139912333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contents Vol. 40, 2023 目 录 第 40 卷,2023 年
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-12-01 DOI: 10.1159/000535458
De Pastena, S. Brozzetti, M. Carati, A. V. Sterpetti, Rome, S. R. Henriksen, J. Rosenberg, S. Fonnes, Herlev, G. Mendez-Rico, D. Reyes-Ruiz, P. I. J.M. Moreno-Ley
{"title":"Contents Vol. 40, 2023","authors":"De Pastena, S. Brozzetti, M. Carati, A. V. Sterpetti, Rome, S. R. Henriksen, J. Rosenberg, S. Fonnes, Herlev, G. Mendez-Rico, D. Reyes-Ruiz, P. I. J.M. Moreno-Ley","doi":"10.1159/000535458","DOIUrl":"https://doi.org/10.1159/000535458","url":null,"abstract":"","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139018188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contents Vol. 39, 2022 目录2022年第39卷
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-04-27 DOI: 10.1159/000530198

Dig Surg 2022;39:I–VI
中华外科杂志(英文版);2009;31 (1):1 - 6
{"title":"Contents Vol. 39, 2022","authors":"","doi":"10.1159/000530198","DOIUrl":"https://doi.org/10.1159/000530198","url":null,"abstract":"<br />Dig Surg 2022;39:I–VI","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Front & Back Matter 正面和背面
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-04-01 DOI: 10.1159/000530871
{"title":"Front & Back Matter","authors":"","doi":"10.1159/000530871","DOIUrl":"https://doi.org/10.1159/000530871","url":null,"abstract":"","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43475758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Society News 社会新闻
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-03-30 DOI: 10.1159/000530303

Dig Surg
{"title":"Society News","authors":"","doi":"10.1159/000530303","DOIUrl":"https://doi.org/10.1159/000530303","url":null,"abstract":"<br />Dig Surg","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of Preoperative Predictors of Pathological Complicated Appendicitis. 病理性复杂性阑尾炎术前预测因子的有效性。
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.1159/000531284
Masahiro Shiihara, Yasuhiro Sudo, Norimasa Matsushita, Takeshi Kubota, Yasuhiro Hibi, Harushi Osugi, Tatsuo Inoue

Introduction: Complicated appendicitis (CA) is often indicated for emergency surgery; however, preoperative predictors of pathological CA (pCA) remain unclear. Furthermore, characteristics of CA that can be treated conservatively have not yet been established.

Methods: 305 consecutive patients diagnosed with acute appendicitis were reviewed. The patients were divided into two groups: an emergency surgery and a conservative treatment group. The emergency surgery group was pathologically classified as having uncomplicated appendicitis (pUA) and pCA, and the preoperative predictors of pCA were retrospectively assessed. Based on the preoperative pCA predictors, a predictive nomogram whether conservative treatment would be successful or not was created. The predictors were applied to the conservative treatment group, and the outcomes were investigated.

Results: In the multiple logistic regression analysis of the factors contributing to pCA, C-reactive protein ≥3.5 mg/dL, ascites, appendiceal wall defect, and periappendiceal fluid collection were independent risk factors. Over 90% of cases without any of the above four preoperative pCA predictors were pUA. The accuracy of the nomogram was 0.938.

Conclusion: Our preoperative predictors and nomogram are useful to aid in distinguishing pCA and pUA and to predict whether or not conservative treatment will be successful. Some CA can be treated with conservative treatment.

简介:复杂性阑尾炎(CA)常指急诊手术;然而,病理性CA (pCA)的术前预测因素尚不清楚。此外,可以保守治疗的CA的特征尚未确定。方法:回顾性分析305例急性阑尾炎患者的临床资料。患者分为两组:紧急手术组和保守治疗组。急诊手术组病理分类为无并发症阑尾炎(pUA)和pCA,回顾性评估pCA术前预测因素。基于术前pCA预测因子,建立保守治疗成功与否的预测图。将预测因子应用于保守治疗组,并观察预后。结果:在对pCA影响因素的多元logistic回归分析中,c反应蛋白≥3.5 mg/dL、腹水、阑尾壁缺损、阑尾周围积液是独立的危险因素。术前无上述四种pCA预测因子的病例中,超过90%为pUA。图的准确度为0.938。结论:我们的术前预测指标和形态图有助于区分pCA和pUA,并预测保守治疗是否成功。有些CA可以保守治疗。
{"title":"Usefulness of Preoperative Predictors of Pathological Complicated Appendicitis.","authors":"Masahiro Shiihara,&nbsp;Yasuhiro Sudo,&nbsp;Norimasa Matsushita,&nbsp;Takeshi Kubota,&nbsp;Yasuhiro Hibi,&nbsp;Harushi Osugi,&nbsp;Tatsuo Inoue","doi":"10.1159/000531284","DOIUrl":"https://doi.org/10.1159/000531284","url":null,"abstract":"<p><strong>Introduction: </strong>Complicated appendicitis (CA) is often indicated for emergency surgery; however, preoperative predictors of pathological CA (pCA) remain unclear. Furthermore, characteristics of CA that can be treated conservatively have not yet been established.</p><p><strong>Methods: </strong>305 consecutive patients diagnosed with acute appendicitis were reviewed. The patients were divided into two groups: an emergency surgery and a conservative treatment group. The emergency surgery group was pathologically classified as having uncomplicated appendicitis (pUA) and pCA, and the preoperative predictors of pCA were retrospectively assessed. Based on the preoperative pCA predictors, a predictive nomogram whether conservative treatment would be successful or not was created. The predictors were applied to the conservative treatment group, and the outcomes were investigated.</p><p><strong>Results: </strong>In the multiple logistic regression analysis of the factors contributing to pCA, C-reactive protein ≥3.5 mg/dL, ascites, appendiceal wall defect, and periappendiceal fluid collection were independent risk factors. Over 90% of cases without any of the above four preoperative pCA predictors were pUA. The accuracy of the nomogram was 0.938.</p><p><strong>Conclusion: </strong>Our preoperative predictors and nomogram are useful to aid in distinguishing pCA and pUA and to predict whether or not conservative treatment will be successful. Some CA can be treated with conservative treatment.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10216936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proposal of the Second Cutoff of Serum Carcinoembryonic Antigen Levels to Stratify Patients into Low, Intermediate, and High Risks at Recurrences after Curative Resection of Gastric Cancer. 建议用血清癌胚抗原水平的第二个临界值将胃癌根治性切除术后复发的患者分为低、中、高风险。
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-01-01 Epub Date: 2023-09-12 DOI: 10.1159/000533143
Bin Sato, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Koki Nakanishi, Dai Shimizu, Chie Tanaka, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera

Introduction: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 are widely used for treating various cancers, with cutoff values of 5.0 ng/mL and 37.0 IU/mL, respectively. However, these cutoff values are not for specific diseases or purposes but are uniformly used for any disease and any purpose. It is also unclear as to whether patients are at equal risk of recurrence if they are below the cutoff values. This study aimed to investigate the optimal cutoff of serum tumor markers in the stratification of recurrence risk after curative resection of gastric cancer.

Methods: We constructed a nine-center integrated database of patients who received gastrectomy between January 2010 and December 2014 with a 5-year follow-up period. We determined the cutoff value of preoperative serum tumor marker levels correlated with postoperative recurrences and evaluated its performance in risk stratification for recurrences in 948 patients with stage II/III gastric cancer who underwent radical resection.

Results: The hazard ratio for postoperative recurrences increased at two points of preoperative CEA levels, 3.6 ng/mL and 5.0 ng/mL, which were set as cutoffs. These two cutoffs stratified relapse-free survival into three levels.

Conclusions: By adding a second cutoff value for preoperative serum CEA, which was proposed specifically for the prediction of recurrences, patients can be stratified into low-, intermediate-, and high-risk recurrences after curative resection of gastric cancer.

导言:癌胚抗原(CEA)和碳水化合物抗原 19-9 被广泛用于治疗各种癌症,其临界值分别为 5.0 纳克/毫升和 37.0 IU/毫升。然而,这些临界值并非针对特定疾病或目的,而是统一用于任何疾病和任何目的。此外,目前还不清楚低于临界值的患者是否具有同等的复发风险。本研究旨在探讨血清肿瘤标志物在胃癌根治性切除术后复发风险分层中的最佳临界值:我们建立了一个九个中心的综合数据库,收录了 2010 年 1 月至 2014 年 12 月间接受胃切除术的患者,随访期为 5 年。我们确定了与术后复发相关的术前血清肿瘤标志物水平的临界值,并评估了其在对948例接受根治性切除术的II/III期胃癌患者进行复发风险分层时的表现:术前CEA水平在3.6纳克/毫升和5.0纳克/毫升这两个临界点时,术后复发的危险比增加。这两个临界值将无复发生存率分为三个等级:通过增加术前血清CEA的第二个临界值(该临界值是专门为预测复发而提出的),可将胃癌根治性切除术后复发的患者分为低、中、高三个风险等级。
{"title":"Proposal of the Second Cutoff of Serum Carcinoembryonic Antigen Levels to Stratify Patients into Low, Intermediate, and High Risks at Recurrences after Curative Resection of Gastric Cancer.","authors":"Bin Sato, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Koki Nakanishi, Dai Shimizu, Chie Tanaka, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera","doi":"10.1159/000533143","DOIUrl":"10.1159/000533143","url":null,"abstract":"<p><strong>Introduction: </strong>Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 are widely used for treating various cancers, with cutoff values of 5.0 ng/mL and 37.0 IU/mL, respectively. However, these cutoff values are not for specific diseases or purposes but are uniformly used for any disease and any purpose. It is also unclear as to whether patients are at equal risk of recurrence if they are below the cutoff values. This study aimed to investigate the optimal cutoff of serum tumor markers in the stratification of recurrence risk after curative resection of gastric cancer.</p><p><strong>Methods: </strong>We constructed a nine-center integrated database of patients who received gastrectomy between January 2010 and December 2014 with a 5-year follow-up period. We determined the cutoff value of preoperative serum tumor marker levels correlated with postoperative recurrences and evaluated its performance in risk stratification for recurrences in 948 patients with stage II/III gastric cancer who underwent radical resection.</p><p><strong>Results: </strong>The hazard ratio for postoperative recurrences increased at two points of preoperative CEA levels, 3.6 ng/mL and 5.0 ng/mL, which were set as cutoffs. These two cutoffs stratified relapse-free survival into three levels.</p><p><strong>Conclusions: </strong>By adding a second cutoff value for preoperative serum CEA, which was proposed specifically for the prediction of recurrences, patients can be stratified into low-, intermediate-, and high-risk recurrences after curative resection of gastric cancer.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk. 阿特唑单抗联合贝伐单抗治疗肝细胞癌伴门静脉主干肿瘤血栓后的病理完全缓解
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.1159/000529405
Ken Kurisaki, Akihiko Soyama, Takanobu Hara, Hajime Matsushima, Hajime Imamura, Takayuki Tanaka, Tomohiko Adachi, Shinichiro Ito, Kengo Kanetaka, Masaaki Hidaka, Shinji Okano, Susumu Eguchi

We report a case of pathologic complete response after successful treatment for advanced hepatocellular carcinoma (HCC) complicated with portal venous tumor thrombus with atezolizumab and bevacizumab followed by radical resection. The patient was a male in his 60s. During follow-up for chronic hepatitis B, abdominal ultrasonography revealed a huge tumor located in the right lobe of the liver with the portal vein thrombosed by the tumor. The tumor thrombus extended to the proximal side of the left branch of the portal vein. The patient's tumor marker levels were elevated (alpha-phetoprotein, 14,696 ng/mL; PIVKA-II, 2,141 mAU/mL). Liver biopsy revealed poorly differentiated HCC. The lesion was categorized as advanced stage according to the BCLC staging system. As systemic therapy, atezolizumab plus bevacizumab was administered. Imaging showed marked shrinkage of the tumor and portal venous thrombus with a remarkable decrease of tumor marker levels after 2 courses of chemotherapy. After 3 additional courses of chemotherapy, radical resection was considered possible. The patient underwent right hemihepatectomy and portal venous thrombectomy. A pathological examination revealed a complete response. In conclusion, we experienced a case in which advanced HCC was curatively treated with atezolizumab plus bevacizumab, which was administered as systemic therapy with a view to conversion surgery.

我们报告一个病例的病理完全缓解后成功治疗晚期肝细胞癌(HCC)合并门静脉肿瘤血栓阿特唑单抗和贝伐单抗根治性切除。患者是一名60多岁的男性。在慢性乙型肝炎的随访中,腹部超声检查显示肝脏右叶有一个巨大的肿瘤,肿瘤形成门静脉血栓。肿瘤血栓延伸至门静脉左支近端。患者肿瘤标志物水平升高(α -光蛋白,14,696 ng/mL;PIVKA-II, 2141 mAU/mL)。肝活检显示低分化HCC。根据BCLC分期系统,病变被归类为晚期。作为全身治疗,使用atezolizumab加贝伐单抗。化疗2个疗程后影像学显示肿瘤及门静脉血栓明显缩小,肿瘤标志物水平明显降低。经过3个疗程的化疗后,认为根治性切除是可能的。患者行右半肝切除术及门静脉取栓术。病理检查显示完全反应。总之,我们经历了一例晚期HCC采用atezolizumab + bevacizumab治疗的病例,这是一种全身治疗,目的是进行转换手术。
{"title":"Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk.","authors":"Ken Kurisaki,&nbsp;Akihiko Soyama,&nbsp;Takanobu Hara,&nbsp;Hajime Matsushima,&nbsp;Hajime Imamura,&nbsp;Takayuki Tanaka,&nbsp;Tomohiko Adachi,&nbsp;Shinichiro Ito,&nbsp;Kengo Kanetaka,&nbsp;Masaaki Hidaka,&nbsp;Shinji Okano,&nbsp;Susumu Eguchi","doi":"10.1159/000529405","DOIUrl":"https://doi.org/10.1159/000529405","url":null,"abstract":"<p><p>We report a case of pathologic complete response after successful treatment for advanced hepatocellular carcinoma (HCC) complicated with portal venous tumor thrombus with atezolizumab and bevacizumab followed by radical resection. The patient was a male in his 60s. During follow-up for chronic hepatitis B, abdominal ultrasonography revealed a huge tumor located in the right lobe of the liver with the portal vein thrombosed by the tumor. The tumor thrombus extended to the proximal side of the left branch of the portal vein. The patient's tumor marker levels were elevated (alpha-phetoprotein, 14,696 ng/mL; PIVKA-II, 2,141 mAU/mL). Liver biopsy revealed poorly differentiated HCC. The lesion was categorized as advanced stage according to the BCLC staging system. As systemic therapy, atezolizumab plus bevacizumab was administered. Imaging showed marked shrinkage of the tumor and portal venous thrombus with a remarkable decrease of tumor marker levels after 2 courses of chemotherapy. After 3 additional courses of chemotherapy, radical resection was considered possible. The patient underwent right hemihepatectomy and portal venous thrombectomy. A pathological examination revealed a complete response. In conclusion, we experienced a case in which advanced HCC was curatively treated with atezolizumab plus bevacizumab, which was administered as systemic therapy with a view to conversion surgery.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9829306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Biologic Mesh and Fundoplication in the Surgical Management of Hiatal Hernias: A Multicenter Evaluation. 生物网状物和底折叠术在先天性疝外科治疗中的作用:多中心评估。
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-01-01 Epub Date: 2023-07-26 DOI: 10.1159/000533186
Cassandra Mohr, Hailie Ciomperlik, Naila Dhanani, Oscar A Olavarria, Craig Hannon, William Hope, Scott Roth, Mike K Liang, Julie L Holihan

Introduction: Hiatal hernia repair is associated with substantial recurrence of both hiatal hernia and symptoms of gastroesophageal reflux (GER). While small randomized controlled trials demonstrate limited differences in outcomes with use of mesh or fundoplication type, uncertainty remains.

Methods: A multicenter, retrospective review of patients undergoing surgical treatment of hiatal hernias between 2015 and 2020 was performed. Patients with mesh and with suture-only repair were compared, and partial versus complete fundoplication was compared. Primary outcomes were hernia recurrence and occurrence of postoperative GER symptoms and dysphagia. Multivariable regression was performed to assess the effect of each intervention on clinical outcomes.

Results: A total of 453 patients from four sites were followed for a median (IQR) of 17 (13) months. On multivariate analysis, mesh had no impact on hernia recurrence (odds ratio 0.993, 95% CI: 0.53-1.87, p = 0.982), and fundoplication type did not impact recurrence of postoperative GER symptoms (complete: odds ratio 0.607, 95% CI: 0.33-1.12, p = 0.112) or dysphagia (complete: odds ratio 1.17, 95% CI: 0.56-2.43, p = 0.677).

Conclusion: During hiatal hernia repair, mesh and fundoplication type do not appear to have substantial impact on GER symptoms, dysphagia, or hernia recurrence. This multicenter study provides real-world evidence to support the findings of small RCTs.

引言:裂孔疝修补术与裂孔疝和胃食管反流(GER)症状的大量复发有关。虽然小型随机对照试验表明,使用网状物或胃底折叠术类型的结果差异有限,但仍存在不确定性。方法:对2015年至2020年间接受裂孔疝手术治疗的患者进行多中心回顾性审查。比较网状和仅缝合修复的患者,并比较部分和完全胃底折叠术。主要结果是疝复发、术后GER症状和吞咽困难的发生。进行多变量回归以评估每种干预措施对临床结果的影响。结果:来自四个部位的453名患者接受了中位(IQR)17(13)个月的随访。在多变量分析中,网状物对疝复发没有影响(比值比0.993,95%CI:0.53-1.87,p=0.982),而胃底折叠术类型对术后GER症状的复发也没有影响(完全:比值比0.607,95%CI:0.33-1.12,p=0.112)或吞咽困难(完全:优势比1.17,95%CI:0.56-2.43,p=0.677),网状物和胃底折叠类型似乎对GER症状、吞咽困难或疝复发没有实质性影响。这项多中心研究提供了真实世界的证据来支持小型随机对照试验的发现。
{"title":"The Role of Biologic Mesh and Fundoplication in the Surgical Management of Hiatal Hernias: A Multicenter Evaluation.","authors":"Cassandra Mohr,&nbsp;Hailie Ciomperlik,&nbsp;Naila Dhanani,&nbsp;Oscar A Olavarria,&nbsp;Craig Hannon,&nbsp;William Hope,&nbsp;Scott Roth,&nbsp;Mike K Liang,&nbsp;Julie L Holihan","doi":"10.1159/000533186","DOIUrl":"10.1159/000533186","url":null,"abstract":"<p><strong>Introduction: </strong>Hiatal hernia repair is associated with substantial recurrence of both hiatal hernia and symptoms of gastroesophageal reflux (GER). While small randomized controlled trials demonstrate limited differences in outcomes with use of mesh or fundoplication type, uncertainty remains.</p><p><strong>Methods: </strong>A multicenter, retrospective review of patients undergoing surgical treatment of hiatal hernias between 2015 and 2020 was performed. Patients with mesh and with suture-only repair were compared, and partial versus complete fundoplication was compared. Primary outcomes were hernia recurrence and occurrence of postoperative GER symptoms and dysphagia. Multivariable regression was performed to assess the effect of each intervention on clinical outcomes.</p><p><strong>Results: </strong>A total of 453 patients from four sites were followed for a median (IQR) of 17 (13) months. On multivariate analysis, mesh had no impact on hernia recurrence (odds ratio 0.993, 95% CI: 0.53-1.87, p = 0.982), and fundoplication type did not impact recurrence of postoperative GER symptoms (complete: odds ratio 0.607, 95% CI: 0.33-1.12, p = 0.112) or dysphagia (complete: odds ratio 1.17, 95% CI: 0.56-2.43, p = 0.677).</p><p><strong>Conclusion: </strong>During hiatal hernia repair, mesh and fundoplication type do not appear to have substantial impact on GER symptoms, dysphagia, or hernia recurrence. This multicenter study provides real-world evidence to support the findings of small RCTs.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10013964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of EGJ Cancer within or outside Clinical Trials: Does the Setting Matter? A Monocentric Prospective Observational Study. 临床试验内外EGJ癌的治疗:环境重要吗?单中心前瞻性观察研究。
IF 2.7 3区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.1159/000529199
Simone Giacopuzzi, Lorena Torroni, Maria Bencivenga, Jacopo Weindelmayer, Maria Clelia Gervasi, Giuseppe Verlato, Michele Pavarana, Gabriella Rossi, Giovanni de Manzoni

Introduction: RCTs support neoadjuvant chemoradiotherapy (nCRT) followed by surgery in locally advanced esophago-gastric junction (LA-EGJ) adenocarcinoma. However, RCTs are performed in highly controlled settings with limited representativeness of real-life patients (RLS). The aim of the study was to compare the outcomes in RLS and clinical trial settings.

Methods: The outcomes of RLS, which comprised 125 patients consequently treated for LA-EGJ adenocarcinoma between 2012 and 2017, were compared with the phase II trial (PIIS), performed on 65 patients from 2003 to 2011.

Results: About half of RLS (51.2%) were treated with nCRT according to VR protocol, 20.8% with standard CRT according to CROSS/Al-Sarraf, 20% with chemotherapy (CT) alone. pCR was 36.8%, 28.6%, and 9.1% after VR protocol, standard CRT, and CT, respectively (p = 0.082), while 3-year overall survival (OS) was 58.6% (95% CI 43.2-71.1%), 32.8% (14.6-52.4%), and 44.8% (21.3-65.9%), respectively (p = 0.030). With respect to PIIS, RLS had a higher proportion of cN+ (94% vs. 54%; p < 0.001) and a lower proportion of pCR after CT/CRT (23% vs. 39%; p = 0.041). Three-year OS was slightly higher, although not significantly, in PIIS (58.9%, 45.1-70.2%) than RLS (47.9%, 37.4-57.7%) and nearly identical to 3-year OS in RLS treated with VR protocol.

Conclusion: Real-life patients with EGJ adenocarcinoma have more advanced cancer at baseline, lower pathologic response to neoadjuvant treatment than patients enrolled in clinical trials, but similar survival.

简介:随机对照试验支持局部晚期食管胃结(LA-EGJ)腺癌的新辅助放化疗(nCRT)后手术治疗。然而,随机对照试验是在高度控制的环境中进行的,对现实患者(RLS)的代表性有限。该研究的目的是比较RLS和临床试验环境的结果。方法:将2012年至2017年期间接受LA-EGJ腺癌治疗的125例RLS患者的结果与2003年至2011年进行的65例II期试验(PIIS)患者的结果进行比较。结果:约一半(51.2%)的RLS患者采用VR方案的nCRT治疗,20.8%的RLS患者采用CROSS/Al-Sarraf标准CRT治疗,20%的RLS患者采用单独化疗(CT)治疗。VR方案、标准CRT和CT后的pCR分别为36.8%、28.6%和9.1% (p = 0.082), 3年总生存率(OS)分别为58.6% (95% CI 43.2-71.1%)、32.8%(14.6-52.4%)和44.8% (21.3-65.9%)(p = 0.030)。相对于PIIS, RLS中cN+的比例更高(94% vs. 54%;p < 0.001), CT/CRT后pCR比例较低(23% vs. 39%;P = 0.041)。PIIS的3年OS(58.9%, 45.1-70.2%)略高于RLS(47.9%, 37.4-57.7%),但不显著,与VR方案治疗的RLS的3年OS几乎相同。结论:与临床试验患者相比,现实生活中的EGJ腺癌患者在基线时更晚期,对新辅助治疗的病理反应更低,但生存期相似。
{"title":"Treatment of EGJ Cancer within or outside Clinical Trials: Does the Setting Matter? A Monocentric Prospective Observational Study.","authors":"Simone Giacopuzzi,&nbsp;Lorena Torroni,&nbsp;Maria Bencivenga,&nbsp;Jacopo Weindelmayer,&nbsp;Maria Clelia Gervasi,&nbsp;Giuseppe Verlato,&nbsp;Michele Pavarana,&nbsp;Gabriella Rossi,&nbsp;Giovanni de Manzoni","doi":"10.1159/000529199","DOIUrl":"https://doi.org/10.1159/000529199","url":null,"abstract":"<p><strong>Introduction: </strong>RCTs support neoadjuvant chemoradiotherapy (nCRT) followed by surgery in locally advanced esophago-gastric junction (LA-EGJ) adenocarcinoma. However, RCTs are performed in highly controlled settings with limited representativeness of real-life patients (RLS). The aim of the study was to compare the outcomes in RLS and clinical trial settings.</p><p><strong>Methods: </strong>The outcomes of RLS, which comprised 125 patients consequently treated for LA-EGJ adenocarcinoma between 2012 and 2017, were compared with the phase II trial (PIIS), performed on 65 patients from 2003 to 2011.</p><p><strong>Results: </strong>About half of RLS (51.2%) were treated with nCRT according to VR protocol, 20.8% with standard CRT according to CROSS/Al-Sarraf, 20% with chemotherapy (CT) alone. pCR was 36.8%, 28.6%, and 9.1% after VR protocol, standard CRT, and CT, respectively (p = 0.082), while 3-year overall survival (OS) was 58.6% (95% CI 43.2-71.1%), 32.8% (14.6-52.4%), and 44.8% (21.3-65.9%), respectively (p = 0.030). With respect to PIIS, RLS had a higher proportion of cN+ (94% vs. 54%; p < 0.001) and a lower proportion of pCR after CT/CRT (23% vs. 39%; p = 0.041). Three-year OS was slightly higher, although not significantly, in PIIS (58.9%, 45.1-70.2%) than RLS (47.9%, 37.4-57.7%) and nearly identical to 3-year OS in RLS treated with VR protocol.</p><p><strong>Conclusion: </strong>Real-life patients with EGJ adenocarcinoma have more advanced cancer at baseline, lower pathologic response to neoadjuvant treatment than patients enrolled in clinical trials, but similar survival.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9819886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Digestive Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1